Report LibraryAll Reports
Datamonitor Healthcare CV&Met: Chronic Heart Failure Pricing, Reimbursement, and Access
April 13, 2018Payers were originally extremely worried about the potential cost burden of Entresto, however, the level of concern surrounding the drug is currently moderate as physician uptake has been lower than expected. Payers suggest that it will take some time for routine prescribing habits to change to incorporate Entresto, as physicians have been treating chronic heart failure patients with cheap angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for many years. If physicians begin requesting Entresto on a frequent basis, then payers across the US and five major EU markets (France, Germany, Italy, Spain, and the UK) indicate that their approaches to the drug’s reimbursement may change.
This Datamonitor Healthcare report contains a Pricing & Reimbursement module.
|Disease Group Covered:||Cardiovascular|